To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Speech in Commons Chamber - Mon 22 Apr 2024
Oral Answers to Questions

Speech Link

View all Andrew Selous (Con - South West Bedfordshire) contributions to the debate on: Oral Answers to Questions

Speech in Commons Chamber - Mon 22 Apr 2024
Oral Answers to Questions

Speech Link

View all Andrew Selous (Con - South West Bedfordshire) contributions to the debate on: Oral Answers to Questions

Division Vote (Commons)
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Andrew Selous (Con) voted Aye - in line with the party majority and in line with the House
One of 299 Conservative Aye votes vs 0 Conservative No votes
Vote Tally: Ayes - 309 Noes - 41
Division Vote (Commons)
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Andrew Selous (Con) voted Aye - in line with the party majority and in line with the House
One of 303 Conservative Aye votes vs 0 Conservative No votes
Vote Tally: Ayes - 312 Noes - 237
Division Vote (Commons)
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Andrew Selous (Con) voted Aye - in line with the party majority and in line with the House
One of 293 Conservative Aye votes vs 1 Conservative No votes
Vote Tally: Ayes - 304 Noes - 222
Division Vote (Commons)
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Andrew Selous (Con) voted Aye - in line with the party majority and in line with the House
One of 302 Conservative Aye votes vs 0 Conservative No votes
Vote Tally: Ayes - 309 Noes - 37
Division Vote (Commons)
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Andrew Selous (Con) voted Aye - in line with the party majority and in line with the House
One of 301 Conservative Aye votes vs 1 Conservative No votes
Vote Tally: Ayes - 305 Noes - 234
Division Vote (Commons)
22 Apr 2024 - Safety of Rwanda (Asylum and Immigration) Bill - View Vote Context
Andrew Selous (Con) voted Aye - in line with the party majority and in line with the House
One of 299 Conservative Aye votes vs 2 Conservative No votes
Vote Tally: Ayes - 306 Noes - 229
Written Question
Incontinence: Products
Monday 22nd April 2024

Asked by: Andrew Selous (Conservative - South West Bedfordshire)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the cost to the NHS of different kinds of absorbent continence products based on the (a) item price and (b) patient experience and outcome including (i) whole system cost, (ii) laundry cost and (iii) environmental impact.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Government is working with NHS England and partner organisations across the health system to develop a standardised methodology, to assess the full value of medical technologies. This initiative underlines our commitment in the Medtech Strategy, published in February 2023, ensuring the right product, in the right place, at the right price. The methodology will seek to look beyond upfront cost to consider patient outcomes, whole system costs, supply resilience, and the environmental impact when procurement decisions are being made.

The methodology will provide a consistent approach to assessing value, and will be implemented at both the national and local level. This approach aims to ensure that procurement decisions support both short-term efficiencies and long-term benefits, drawing out the value to patients and the healthcare system. The Government appreciates contributions from the industry and procurement communities, and will invite stakeholders to provide feedback on the initial proposal in due course.

In terms of implementation, we will look to align and integrate this initiative with NHS England’s Central Commercial Function's ongoing work under their strategic framework, which aims to create commercial playbooks for standardising practices and processes across the National Health Service.

Regarding the specific point raised around absorbent continence products, the Disposable Continence tender is due to be issued to the market later this year. To ensure that the NHS’s requirements are considered during the procurement process, NHS Supply Chain is undertaking significant engagement across the health and social care system. This includes customers in the acute and wider community setting, suppliers, trade associations, professional bodies, and end user reference groups, to understand their requirements from a commercial, value, sustainability, and supply resilience perspective.

NHS Supply Chain is currently working with suppliers of disposable continence products to understand the value-based procurement and sustainability offerings on the purchase of continence products. NHS Supply Chain has identified a trust who are committed in supporting us in understanding this value in the form of a pilot study, and potential case study. More information can be provided once these studies have been finalised and confirmed.


Written Question
Incontinence: Products
Monday 22nd April 2024

Asked by: Andrew Selous (Conservative - South West Bedfordshire)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether she is taking steps to ensure that NHS organisations take into account (a) patient experience and outcomes, (b) whole system costs, (c) laundry costs and (d) the environmental impact when purchasing absorbent continence products.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Government is working with NHS England and partner organisations across the health system to develop a standardised methodology, to assess the full value of medical technologies. This initiative underlines our commitment in the Medtech Strategy, published in February 2023, ensuring the right product, in the right place, at the right price. The methodology will seek to look beyond upfront cost to consider patient outcomes, whole system costs, supply resilience, and the environmental impact when procurement decisions are being made.

The methodology will provide a consistent approach to assessing value, and will be implemented at both the national and local level. This approach aims to ensure that procurement decisions support both short-term efficiencies and long-term benefits, drawing out the value to patients and the healthcare system. The Government appreciates contributions from the industry and procurement communities, and will invite stakeholders to provide feedback on the initial proposal in due course.

In terms of implementation, we will look to align and integrate this initiative with NHS England’s Central Commercial Function's ongoing work under their strategic framework, which aims to create commercial playbooks for standardising practices and processes across the National Health Service.

Regarding the specific point raised around absorbent continence products, the Disposable Continence tender is due to be issued to the market later this year. To ensure that the NHS’s requirements are considered during the procurement process, NHS Supply Chain is undertaking significant engagement across the health and social care system. This includes customers in the acute and wider community setting, suppliers, trade associations, professional bodies, and end user reference groups, to understand their requirements from a commercial, value, sustainability, and supply resilience perspective.

NHS Supply Chain is currently working with suppliers of disposable continence products to understand the value-based procurement and sustainability offerings on the purchase of continence products. NHS Supply Chain has identified a trust who are committed in supporting us in understanding this value in the form of a pilot study, and potential case study. More information can be provided once these studies have been finalised and confirmed.